Matrix Matters: Head‐To‐Head Concordance of Serum and Plasma for NULISAseq CNS Disease Panel
- 5 November 2026
- journal article
- Published by Wiley in Journal of Neurochemistry
- Vol. 170 (11)
Abstract
Blood‐based proteomic profiling is now widely applied in neurodegenerative and neuroinflammatory disease, yet the choice between serum and plasma remains poorly characterised for high‐multiplex platforms. Many biobanks consist predominantly of serum, whereas most current NUcleic‐acid‐Linked Immuno‐Sandwich Assay (NULISA) studies use plasma. We compared the 130‐protein NULISAseq central nervous system (CNS) Disease Panel head‐to‐head in matched serum and plasma collected at the same venipuncture from 62 participants (30 neurodegenerative, 19 demyelinating, 13 healthy controls). Agreement was measured with Spearman correlation (rho), Lin's concordance correlation coefficient (CCC), the intraclass correlation coefficient (ICC) and the mean paired plasma‐minus‐serum difference (dNPQ). Concordance was moderate to high: 114 of 130 proteins reached FDR significance and 18 reached rho ≥ 0.90, with a median rho of 0.65 (range 0.010–0.988). Proteins were classified into three concordance tiers (31, 6 and 30 proteins), with the remaining 63 showing intermediate concordance. Cytoskeletal markers (NEFH rho = 0.988; NEFL rho = 0.947) and glial GFAP (rho = 0.949, |dNPQ| < 0.5) were interchangeable between matrices. Phosphorylated tau (pTau) species retained excellent rank concordance but showed a systematic plasma‐greater‐than‐serum offset (pTau‐181 rho = 0.869, dNPQ = +0.67; pTau‐217 rho = 0.846, dNPQ = +0.64; pTau‐231 rho = 0.885, dNPQ = +0.89). Platelet‐derived analytes (CD40LG rho = 0.102, dNPQ = −4.74; BDNF rho = 0.223, dNPQ = −2.69) and intracellular synaptic proteins (NRGN, SNAP25, ENO2) diverged markedly. For most clinically relevant neurodegeneration markers, especially cytoskeletal and glial proteins, serum is a valid substitute for plasma; absolute thresholds for phosphorylated tau require matrix‐specific calibration, whereas amyloid peptides and platelet‐sensitive analytes cannot be reliably compared across matrices without strictly standardised pre‐analytical conditions. imageKeywords
Funding Information
- European Commission (PE0000006)
- Ministero della Salute (PNRR‐MAD‐2022‐12376110)
This publication has 33 references indexed in Scilit:
- GPND‐AI NULISA: A 15‐Protein AI classifier for diagnosis and co‐pathology profiling across neurodegenerative diseasesAlzheimer's & Dementia, 2026
- Evidence‐based standardized sample handling protocol for accurate blood‐based Alzheimer's disease biomarker measurement: Results and consensus of the Global Biomarker Standardization ConsortiumAlzheimer's & Dementia, 2025
- Alzheimer's Association Clinical Practice Guideline on the use of blood‐based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settingsAlzheimer's & Dementia, 2025
- Biomarker discovery in Alzheimer's and neurodegenerative diseases using Nucleic Acid Linked Immuno‐Sandwich AssayAlzheimer's & Dementia, 2025
- Targeted proteomic biomarker profiling using NULISA in a cohort enriched with risk for Alzheimer's disease and related dementiasAlzheimer's & Dementia, 2025
- Diagnostic accuracy of plasma p‐tau217/Aβ42 for Alzheimer's disease in clinical and community cohortsAlzheimer's & Dementia, 2025
- Novel plasma biomarkers of amyloid plaque pathology and cortical thickness: Evaluation of the NULISA targeted proteomic platform in an ethnically diverse cohortAlzheimer's & Dementia, 2025
- Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association WorkgroupAlzheimer's & Dementia, 2024
- Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease PathologyJAMA Neurology, 2024
- Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative DisordersJAMA, 2020